10 clinical trials to watch in the second half of 2023

The next six months will be full of dramatic moments for the biotechnology industry.

The Food and Drug Administration will either be validated or undermined for its decision to grant an early approval to the first gene therapy for Duchenne muscular dystrophy. A non-addictive pain pill could finally materialize, or fall short like others before it. A closely watched group of cancer drugs might rebound after a series of setbacks, while another could show a new way to treat multiple sclerosis. And a popular group of diabetes and weight-loss drugs will get data on whether they prevent heart attacks, too.